Why It Matters

[Walgreen Co.](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) is a longstanding lobbying player with two decades of federal advocacy experience and $63 million in total spending. The company likely faces significant policy impacts from its three Q3 2025 focus areas. PBM reform legislation could reshape pharmacy reimbursement models and competitive dynamics. Organized retail crime legislation directly addresses operational losses from theft affecting Walgreens’ bottom line. Tax policy changes could influence corporate profitability and structure. [Walgreens](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) is maintaining its in-house lobbying approach while retaining specialized external firms including [Brownstein Hyatt Farber Schreck LLP](https://app.legis1.com/lobbying-firm/detail?organizationId=44966&actorId=2963#summary), [Wilmer Cutler Pickering Hale & Dorr LLP](https://app.legis1.com/lobbying-firm/detail?organizationId=62089&actorId=2857#summary), and [West Front Strategies LLC](https://app.legis1.com/lobbying-firm/detail?organizationId=127434&actorId=219955#summary). The Q3 2025 spending of $620,000 represents consistent engagement on issues where Congress is actively considering legislation. [Walgreens](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) is joining a broader pharmacy retail coalition—including [Kroger Co.](https://app.legis1.com/lda-filings/detail?id=1952806#summary), [CVS Health](https://app.legis1.com/lda-filings/detail?id=2007380#summary), and [Albertsons Cos. Inc.](https://app.legis1.com/lda-filings/detail?id=1978249#summary)—lobbying on identical pharmacy reform bills.

By the Numbers

[Walgreen Co.](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) spent **$620,000** in Q3 2025 through its in-house lobbying operation, which began in 2006. The company has spent over **$63 million** on federal advocacy since 2003, with **$45.9 million** attributed to in-house lobbying across 72 disclosures. Walgreens’ Q3 2025 lobbying team consists of two registered lobbyists: **Madeline Kroll Hodge** and **Isaac A. Fordjour**. Historically, the company has also retained external firms including [Potomac Group](https://app.legis1.com/lobbying-firm/detail?organizationId=54765&actorId=169271#summary), [Brownstein Hyatt Farber Schreck LLP](https://app.legis1.com/lobbying-firm/detail?organizationId=44966&actorId=2963#summary), [Wilmer Cutler Pickering Hale & Dorr LLP](https://app.legis1.com/lobbying-firm/detail?organizationId=62089&actorId=2857#summary), [West Front Strategies LLC](https://app.legis1.com/lobbying-firm/detail?organizationId=127434&actorId=219955#summary), [ACG Advocacy LLC](https://app.legis1.com/lobbying-firm/detail?organizationId=66064&actorId=169882#summary), and [Forbes Tate Partners LLC](https://app.legis1.com/lobbying-firm/detail?organizationId=49047&actorId=57837#summary). Pharmacy and Medicare/Medicaid issues have dominated all 72 in-house filings, while consumer protection appears in 39 filings and tax policy in 26 filings.

The Agenda

[Walgreen Co.](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) is lobbying on three core issues during Q3 2025: pharmacy benefit manager (PBM) reform, organized retail crime prevention, and corporate tax policy.

On pharmacy issues, Walgreens is specifically advocating on [H.R. 3164 (Ensuring Community Access to Pharmacist Services Act)](https://app.legis1.com/bill/detail?id=3164_119_HR#summary), [H.R. 4317 (Pharmacy Benefit Manager Reform Act)](https://app.legis1.com/bill/detail?id=4317_119_HR#summary), [H.R. 2484 (Seniors’ Access to Critical Medications Act)](https://app.legis1.com/bill/detail?id=2484_119_HR#summary), the 340B drug discount program, and vaccine access matters. On consumer protection, the company is lobbying on [H.R. 2853 (Combatting Organized Retail Crime Act)](https://app.legis1.com/bill/detail?id=2853_119_HR#summary). On tax issues, Walgreens is engaged on [H.R. 1 (One Big Beautiful Bill Act)](https://app.legis1.com/bill/detail?id=1_119_HR#summary) and the Work Opportunity Tax Credit.

Broader Context

Walgreens’ Q3 2025 lobbying activities occur within a landscape of significant congressional momentum on multiple fronts. Congress is actively pursuing comprehensive pharmacy benefit manager (PBM) reform, with bipartisan frustration over drug pricing and market consolidation driving legislative action. Three PBMs control approximately 80% of the market, prompting [Federal Trade Commission scrutiny](https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-releases-second-interim-staff-report-prescription-drug-middlemen) and multiple bills including [H.R. 4317](https://www.quiverquant.com/news/New+Bill%3A+Representative+Earl+L.+%22Buddy%22+Carter+introduces+H.R.+4317%3A+Pharmacy+Benefit+Manager+Reform+Act+of+2025), which Walgreens is actively lobbying on. Simultaneously, Congress is addressing organized retail crime at the federal level, creating opportunities for pharmacy retailers to shape legislation like the Combatting Organized Retail Crime Act. Additionally, major tax reform legislation including the “One Big Beautiful Bill Act” presents opportunities for Walgreens to influence corporate tax policy affecting its operations.

Between The Lines

Congress is actively pursuing comprehensive pharmacy benefit manager (PBM) reform with significant bipartisan momentum. The [House Energy and Commerce Committee](https://app.legis1.com/hearings/detail?id=41105#summary) and [Senate Judiciary Committee](https://app.legis1.com/hearings/detail?id=42749#summary) have held hearings highlighting market consolidation concerns, with members noting that three PBMs control over 80% of the market. Key legislation aligns with Walgreens’ priorities, including [H.R. 4317](https://www.quiverquant.com/news/New+Bill%3A+Representative+Earl+L.+%22Buddy%22+Carter+introduces+H.R.+4317%3A+Pharmacy+Benefit+Manager+Reform+Act+of+2025), introduced by Rep. Buddy Carter (R-GA), a pharmacist. Companion bills like the [S.526 – Pharmacy Benefit Manager Transparency Act of 2025](https://app.legis1.com/bill/detail?id=526_119_S#summary) and [S.882 – Patients Before Middlemen Act](https://app.legis1.com/bill/detail?id=882_119_S#summary) target similar PBM reforms. On organized retail crime, [H.R. 2853 – Combatting Organized Retail Crime Act](https://app.legis1.com/bill/detail?id=2853_119_HR#summary) is advancing with support from members including Rep. David Valadao. The [Senate HELP Committee](https://app.legis1.com/hearings/detail?id=43771#summary) has also scrutinized the **340B Drug Pricing Program**, raising concerns about discounts reaching low-income patients. Major retailers including [Kroger Co.](https://app.legis1.com/lda-filings/detail?id=1952806#summary), [CVS Health](https://app.legis1.com/lda-filings/detail?id=2007380#summary), and [Albertsons Cos. Inc.](https://app.legis1.com/lda-filings/detail?id=1978249#summary) are lobbying on similar issues, creating unified industry advocacy.

Competitive Landscape

Walgreens operates within a crowded competitive lobbying landscape on pharmacy reform. [Kroger Co.](https://app.legis1.com/lda-filings/detail?id=1952806#summary), [CVS Health](https://app.legis1.com/lda-filings/detail?id=2007380#summary), [Albertsons Cos. Inc.](https://app.legis1.com/lda-filings/detail?id=1978249#summary), and [FMI, The Food Industry Association](https://app.legis1.com/lda-filings/detail?id=2009968#summary) are also actively lobbying on PBM reform legislation. This coalition of pharmacy retailers is creating a unified front on many of the same bills. On organized retail crime, Kroger has similarly lobbied on the INFORM Consumers Act and broader ORC issues, demonstrating industry-wide concern about theft and supply chain security. The retail pharmacy sector presents a rare united advocacy posture across competing retailers, suggesting strong consensus around regulatory priorities in the current congressional environment.

The Bottom Line

[Walgreen Co.](https://app.legis1.com/organizations/detail?clientLobbyActorId=348&organizationId=38663#summary) spent $620,000 in Q3 2025 lobbying Congress on three core policy areas: pharmacy benefit manager reform, organized retail crime legislation, and tax policy. The company deployed two in-house lobbyists—[Madeline Kroll Hodge](https://app.legis1.com/lobbyist/detail?personId=201365&actorId=222910#summary) and [Isaac A. Fordjour](https://app.legis1.com/lobbyist/detail?personId=92809&actorId=95819#summary)—to engage on bills including [H.R. 4317](https://www.quiverquant.com/news/New+Bill%3A+Representative+Earl+L.+%22Buddy%22+Carter+introduces+H.R.+4317%3A+Pharmacy+Benefit+Manager+Reform+Act+of+2025), [H.R. 2853](https://app.legis1.com/bill/detail?id=2853_119_HR#summary), and major tax reform. Walgreens’ advocacy reflects broader congressional momentum on PBM reform, retail crime prevention, and federal drug pricing policy. The company is part of a larger pharmacy retail coalition lobbying on similar issues, consistent with its two-decade history of federal advocacy on healthcare and pharmacy-related matters.